Publicly funded trial finds psilocybin eases treatment-resistant depression
TL;DR Summary
A publicly funded randomized trial found that a 25mg dose of psilocybin plus psychological support significantly boosted response (43% at 3 weeks, 56% at 6 weeks) and remission (40% at 3 weeks vs 3% placebo), with effects sustained through six weeks, suggesting psilocybin therapy could help treatment-resistant depression and warrants larger, publicly funded trials in community settings.
- Magic mushrooms can ease depression resistant to other treatments, major study finds The Independent
- Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial Nature
- Psychedelic in magic mushrooms can ease depression The Telegraph
- Single dose of psilocybin for depression shows promising results in UK's first publicly funded randomized trial Medical Xpress
- Psilocybin Has Crossed the Evidence Threshold. Clinical Guidelines Have Not. The Clinical Trial Vanguard
Reading Insights
Total Reads
0
Unique Readers
4
Time Saved
12 min
vs 13 min read
Condensed
98%
2,434 → 57 words
Want the full story? Read the original article
Read on The Independent